Open AccessAlpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
Author(s) -
Anne Jacobson
Publication year - 2022
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1093/oncolo/oyac011
Subject(s) - medicine , letrozole , fulvestrant , oncology , breast cancer , her2 negative , metastatic breast cancer , cancer , gynecology , aromatase , tamoxifen
Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom